Opendata, web and dolomites

RECOBIN-PROTACs SIGNED

Reversible Covalently Binding PROTACs Technology for Protein Degradation in Cancer Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RECOBIN-PROTACs project word cloud

Explore the words cloud of the RECOBIN-PROTACs project. It provides you a very rough idea of what is the project "RECOBIN-PROTACs" about.

rt53    stability    causing    efficient    off    ligase    linker    cancer    blood    bone    cysteine    discovery    protacs    enzyme    lines    protease    residue    aggressive    connected    receives    poor    medicine    proteolysis    site    drug    specificity    molecule    active    lack    immolative    connects    proliferation    aml    reactive    therapeutic    antibody    linkers    inside    conjugates    proximal    self    labile    modalities    synthesis    marrow    utility    ligand    modification    cells    therapies    degradation    e3    masked    myeloid    limit    degraders    chimeras    tools    covalently    leukemia    conjugated    molecules    proximity    affinity    small    enhances    group    permeability    forms    interactions    library    tested    ligands    consists    cell    cleavage    binding    modern    lys    covalent    protac    bet    chemoselective    inhibit    concentrations    uses    selectively    today    recobin    rational    functional    protein    inhibition    proteins    labeling    handle    stabilizing    intervention    stable    generate    healthy    acute    flexible    ternary    release    disease    technique    reversible   

Project "RECOBIN-PROTACs" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 224˙933 €
 EC max contribution 224˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 224˙933.00

Map

 Project objective

Today's challenge for modern medicine is the development of tools that can selectively target cancer cells over healthy cells. Acute myeloid leukemia (AML) is an aggressive blood cancer of the myeloid cells causing bone marrow failure. Drug development research uses small molecules to inhibit the activity of proteins promoting cell proliferation. The higher concentrations of drug required for efficient inhibition often lead to off-target effects. Recent years, proteolysis targeting chimeras (PROTACs) technique receives much attention for therapeutic intervention by degradation of disease-causing proteins. However, the requirements of PROTACs such as high affinity and specificity ligands, poor stability, cell permeability, lack of cell specificity limit the broader utility of this technique. Here, we propose a novel rational design and synthesis of reversible covalently binding PROTACs (RECOBIN-PROTACs) based on the proximity labeling. A RECOBIN-PROTAC molecule consists of target protein ligand, E3 ligase ligand and a chemoselective functional group connected through flexible linkers. The chemoselective functional group forms reversible covalent modification with proximal Lys residue of BET protein or E3 ligase. This proximity labeling enhances the binding affinity of the ligands to the targets, stabilizing protein-protein interactions in ternary complex formation. The library of RT53 based RECOBIN-PROTACs will be tested on AML cell lines to find most efficient degraders. Also, the chemoselective group masked by self-immolative linker connects with enzyme-labile group and cysteine reactive handle. The most efficient RT53 based RECOBIN-PROTACs will be conjugated site-selectively to cysteine antibody to generate stable RECOBIN-PROTAC-Antibody Conjugates. These conjugates selectively release the active RECOBIN-PROTAC inside the target cells upon protease cleavage. The features of RECOBIN-PROTACs technology will bring new modalities in therapies and drug discovery.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RECOBIN-PROTACS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RECOBIN-PROTACS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

CORRELATION (2020)

Characterization and prediction of service-level traffic for future sliced mobile network

Read More  

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More